Invivyd announces positive Liberty Phase 3 results and plans regulatory submission for Vyd2311
IVVD•Invivyd reported positive topline results from its Liberty Phase 3 study, saying Vyd2311 had superior safety and tolerability to an mRNA-based COVID-19 vaccine. The company plans to submit a biologics license application to the FDA through its accelerated approval program.
1. Study results and plans
Invivyd said Vyd2311 demonstrated safety and tolerability superior to an mRNA-based COVID-19 vaccine in the Liberty Phase 3 study. The company said Vyd2311 combined with an mRNA COVID-19 vaccine added to neutralizing titers without interference, and it plans an FDA biologics license application submission through the accelerated approval program.
